VANCOUVER, BC, May 30, 2024
/CNW/ - Numinus Wellness Inc. ("Numinus" or the
"Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care
company advancing traditional and innovative behavioral health
treatments with a focus on safe, evidence-based
psychedelic-assisted therapies, announces that Health Canada has
approved the Company's Clinical Trial Application to examine the
feasibility of a group model in MDMA-assisted psychotherapy
enrolling trainee practitioners as participants.
The study aims to enhance comprehension of the ideal number of
therapists needed to administer MDMA-assisted psychotherapy group
sessions effectively. Additionally, the trial offers eligible
trainees the chance to develop core competencies through observing
seasoned therapists conduct MDMA-assisted psychotherapy sessions
and legally experience MDMA themselves in a therapeutic setting as
healthy research subjects.
"We are pleased to have received approval for this study, which
will be the first of its kind to investigate the viability of a
group therapy model, establish the best methods for MDMA group
therapy, and add to the existing research supporting its safe use,"
said Payton Nyquvest, Numinus
Founder and CEO. "Considering the growing body of research into the
potential benefits of MDMA for treating severe mental disorders,
such as PTSD, it's essential that medical professionals enhance
their understanding of how best to administer it in a clinical
environment."
The clinical trial is formally titled "Phase 1 Exploration of
Feasibility and Optimal Therapist Numbers in Group Model
MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and
Practitioner Training."
"This study could greatly improve therapist understanding of the
effects of MDMA, therapist skills, and patient outcomes by offering
practitioners a chance to gain crucial insights into different
modalities of treatment," added Rick
Doblin, PhD., an unpaid volunteer Numinus Strategic Advisor.
"This will become important should MDMA treatment for PTSD receive
FDA approval with a significant number of patients in need of
care."
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be
well through the development and delivery of innovative mental
health care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model – including psychedelic research,
clinic care and practitioner training – is at the forefront of a
transformation aimed at healing rather than managing symptoms for
depression, anxiety, trauma, pain and substance use. At Numinus, we
are leading the integration of psychedelic-assisted therapies into
mainstream clinical practice and building the foundation for a
healthier society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-looking statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements. Forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate",
"believe", "plan", "estimate", "expect" and "intend" and statements
that an event "may", "will", "should", "could" or "might" occur or
other similar expressions. Forward-looking statements are subject
to risks and uncertainties and other factors that could cause
actual results to differ materially from those contained in the
forward-looking statements, including approval of MDMA-assisted
therapy for any indication or at all; restrictions that may be
placed on the use of MDMA by regulatory authorities; safety and
efficacy of MDMA-assisted therapy; acceptance, uptake and
commercialization of MDMA-assisted therapy; timing and completion
of the clinical trial; availability of suitable subjects for the
trial; and other risks that are set forth in our annual information
form dated November 29, 2023 and
available on SEDAR at www.sedarplus.ca.
Forward-looking statements are based on estimates and opinions of
management at the date the statements are made. Numinus does not
undertake any obligation to update forward-looking statements even
if circumstances or management's estimates or opinions should
change except as required by applicable laws. Investors should not
place undue reliance on forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/numinus-wellness-receives-health-canada-approval-for-study-into-group-model-for-mdma-assisted-therapy-302158703.html
SOURCE Numinus Wellness Inc.
